August 12, 2019

ASH ® 2019 Review Faculty

Binay Shah, MD, MHA – Binaytara Foundation

Dr. Binay Shah is a board certified oncologist and hematologist at PeaceHealth United General Hospital, Sedro Woolley, WA. Dr. Shah’s area of interest is in health outcomes and health disparities among cancer patients, and he has published and presented over 125 papers in various journals and meetings.

He is invited nationally and internationally to speak on various cancers and global health. He has the distinction of developing the nation’s first statewide personalized cancer care tumor board as  president of the Idaho Society of Clinical Oncology. Dr. Shah is a patient advocate, and humanitarian. He founded the Binaytara Foundation to promote health and education in underprivileged communities.


Dr. Kumar at BTF’s annual ICAHO meeting

Shaji Kumar, MD – Mayo School of Medicine

Dr. Shaji Kumar is a hematologist at Mayo School of Medicine. His research focuses on development of novel drugs for treatment of myeloma. Dr. Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes.


Dr. Walter at BTF’s ICAHO19 Conference

Roland Walter, MD, PhD, MS – Fred Hutchinson Cancer Research Center

Dr. Roland Walter is a hematologist who specializes in treating acute myeloid leukemia, or AML. His research seeks to develop new and improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate the AML stem cells, and then to bring these therapies to patients.


Dr. Venugopal at BTF’s ICAHO

Parameswaran Venugopal, MD – Rush University Medical Center

Dr. Venugopal, MD is the Elodia Kehm Chair of Hematology; a Professor in the Department of Internal Medicine, and the Director of Hematology Section at the Rush Medical College & Rush University Medical Center.


George Rodgers, MD, PhD – University of Utah Health Sciences Center

George M. Rodgers, MD, PhD is Professor of Medicine and Pathology at the University of Utah Health Sciences Center.  His is also Medical Director of the Coagulation Laboratory at ARUP Laboratories. He received his M.D. and Ph.D. degrees from Tulane University, did internal medicine training at Baylor College of Medicine, and received hematology fellowship training at UCSF.Dr. Rodgers’ clinical research interests include benign hematology, especially disorders of hemostasis and thrombosis.  He has published over 200 journal articles and book chapters as well as 4 books, primarily on coagulation subjects. He is an associate editor of Wintrobe’s Clinical Hematology textbook.


Doris Quon, MD – Orthopedic Hemophilia Treatment Center

Dr. Quon is board certified in Hematology & Oncology and Internal Medicine.  She obtained her M.D., Ph.D. at the UCLA David Geffen School of Medicine and did her Residency in Internal Medicine as well as Fellowship in Hematology-Oncology at UCLA Medical Center.  She first began her residency training at the Orthopedic Hemophilia Treatment Center (OHTC) back in 2000 and is currently a Medical Director of OHTC.  She has an active role in coordinating the federally funded Region IX Hemophilia activities for the center and is the Medical Director of the Hemophilia Foundation of Southern California.


Dr. Patel at BTF’s ICAHO annual meeting

Krish Patel, MD – Swedish Cancer Institute

Krish Patel is a clinical investigator and Director of the Lymphoma Program at the Swedish Cancer Institute (SCI) in Seattle, Washington.  Dr. Patel completed his medical school, residency, and fellowship training at Duke University School of Medicine where he served as a Chief Resident in Internal Medicine.  In 2016, he joined the Swedish Cancer Institute Center for Blood Disorders and Stem Cell Transplantation as a clinical investigator. Clinically, he is focused on all aspects of lymphoma and CLL related care.  He has a particular research interest in the development of novel targeted agents, immunotherapies, and cellular therapies to advance care for patients with lymphoid malignancies. He is currently a principal investigator for numerous phase I-III therapeutic lymphoma and CLL clinical trials at SCI.


Mazyar Shadman, MD, MPH – Fred Hutchinson Cancer Research Center

Mazyar Shadman, MD, MPH, is an assistant member at Fred Hutchinson Cancer Research Center and an assistant professor of medicine at University of Washington (UW). He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell) and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL.  He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies. Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He returned to Seattle and finished his training in hematology and medical oncology fellowships at the UW and Fred Hutchinson cancer research center. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.


Dr. Tantravahi at BTF’s Annual ICAHO meeting

Srinivas Tantravahi, MDUniversity of Utah Health Sciences Center

Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. The focus of his research has been on the mechanisms of resistance of CML patients to tyrosine kinase inhibitor therapy. Sri and his colleagues demonstrated that TKI resistance arises from both mutations in the BCR-ABL1 kinase and other cellular pathways. Through his research on chronic myeloid leukemia, he successfully leveraged a competitive Research Training Award from the American Society of Hematology to extend his research work. During his residency and fellowship Dr. Tantravahi published 14 manuscripts in peer-reviewed journals. His clinical work at Huntsman Cancer Institute includes chronic myeloid malignancies, multiple myeloma and bone marrow transplantation.